Found 7318 matches for
The University of Oxford and Bayer HealthCare have entered into a strategic research alliance in the area of gynaecological therapies. The multi-target collaboration focuses on endometriosis and uterine fibroids with the goal of discovering and developing innovative treatment options for these diseases. The alliance is for an initial period of two years, but is open for extension to up to five years.
The Morten research group aims to bring forward the day when ME/CFS can be cured, through cutting-edge biomedical research.
The Deep Medicine programme combines pioneering data analytic approaches, deep and machine learning techniques, and interdisciplinary collaboration to generate insights that will help tackle some of the major causes of death and disability worldwide.
The Nuffield Department of Women's & Reproductive health is part of the Oxford University Global Surgery Group (OUGSG), a interdepartmental group of the Medical Sciences Division for clinicians in surgery, anaesthesia, obstetrics and gynaecology with an interest in global surgical issues.
The placenta is the most indispensable, disposable organ you ever had. It decrees both how well we grow and develop in the womb and our future health well into adulthood. Our research explores two key themes: 1) Imaging the placenta early in pregnancy in order to predict adverse pregnancy outcomes including fetal growth restriction and 2) Diagnosis and management of Placenta Accreta Spectrum Disorder (PAS) - also known as abnormally invasive placenta (AIP).
Today, over 55% of the world’s population live in urban areas, with growth expected to accelerate in low-income and lower-middle-income countries over the next three decades. In order that this urbanisation is inclusive, safe and sustainable, it must be carefully managed to ensure that city spaces are ready to cater for the health of their expanding communities, and that of future citizens.
Recent advances in medicine and health policy have led to an unprecedented increase in life expectancy. This longevity has also seen an increasing number of people, particularly older adults, suffering from two or more serious chronic diseases - a status known as multimorbidity.
Cardiovascular diseases are the leading cause of death in the world. The work of this research group integrates large databases of electronic health records, clinical trials, meta-analyses and digital technologies to better understand the determinants and consequences of cardiovascular disease, and how to improve quality of care and health outcomes.
Every year, millions of women die from heart disease, stroke and complications of diabetes, with the greatest number of deaths occurring in low-resource settings, such as parts of rural India. Dr Jane Hirst and Dr D Praveen lead the SMARThealth Pregnancy programme, which aims to help community health workers identify women at risk and manage their healthcare in order to reduce premature deaths
Prof Suzannah Williams and her research team have begun work to find a new way of saving the Northern White Rhino by using tissue taken from animal ovaries to produce potentially large numbers of eggs in a laboratory setting.
Developing novel techniques to preserve the fertility of children and young adults.
INGR1D is a large screening study in the Thames Valley to identify infants who are at risk of developing type 1 diabetes.
Our research focuses on the use of nanoparticles in cancer for therapy, imaging or drug delivery.
Assisted Reproductive Technology (ART) research seeks to shed light on the factors responsible for reproductive failure. We are also actively engaged in efforts to improve infertility treatments, such as in vitro fertilisation (IVF). Our work aims to simplify treatments and reduce risks, increase success rates and lower costs.